AACR19

BMS, clinging to Opdivo's lung share, highlights long-term data

After a blow in first-line lung cancer, BMS is clinging to its share of the second-line market. And it’s hoping new long-term data can help it hang on.

Carly Helfand Apr 3, 2019 11:09am

Clovis' Rubraca puts up positive phase 2 pancreatic cancer data

Apr 2, 2019 8:30am

Keytruda spurs long responses in small cell lung cancer

Apr 1, 2019 8:30am